BiotechTube

Sparsentan

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin A Nephropathy

Conditions

Immunoglobulin A Nephropathy

Trial Timeline

May 19, 2023 → Oct 25, 2024

NCT ID
NCT05856760

About Sparsentan

Sparsentan is a phase 2 stage product being developed by Travere Therapeutics for Immunoglobulin A Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05856760. Target conditions include Immunoglobulin A Nephropathy.

What happened to similar drugs?

0 of 4 similar drugs in Immunoglobulin A Nephropathy were approved

Approved (0) Terminated (0) Active (4)
🔄iptacopanNovartisPhase 3
🔄Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
🔄Felzartamab + PlaceboBiogenPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT07219121ApprovedRecruiting
NCT05856760Phase 2Completed
NCT05630612Phase 2Active
NCT04663204Phase 2Active

Competing Products

11 competing products in Immunoglobulin A Nephropathy

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
39
zigakibartNovartisPhase 2
42
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
InebilizumabAmgenPhase 2
42
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
47
rilzabrutinib + GlucocorticoidsSanofiPhase 2
35
FelzartamabBiogenPhase 2
32
Felzartamab + PlaceboBiogenPhase 3
44
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38